NEW YORK, April 5, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the Alzheimer’s disease and other serious neurodegenerative conditions today announced it has received a new patent from the Israeli Patent and Trademark Office related to OX1, the Company’s clinical-stage drug candidate. OX1 is a multimodal, metal-binding, extremely potent antioxidant molecule that has been demonstrated in numerous cell-based and animal models to be exceptionally effective at protecting cells, especially nerve cells, from highly oxidizing conditions caused by oxidotoxins, metabolic inhibitors, heavy metals, neurotoxins such as beta amyloid, and ischemia. OX1, which is orally administered and has the potential to treat a broad spectrum of diseases, was found to be safe, well tolerated and rapidly absorbed into the body in human Phase 1 clinical trials.
